Antioxidants do not prevent heart disease in high-risk individuals

ABSTRACT

BACKGROUND: Several nonrandomized, observational studies have suggested that antioxidant vitamins decrease vascular disease, cancer, and mortality. However, large randomized trials are needed to counter biases such as the “healthy user effect” often seen in observational studies.

POPULATION STUDIED: The investigators studied 20,536 adults (mostly men from the United Kingdom) aged 40 to 80 years with diabetes, peripheral artery disease, or coronary artery disease. Patients were included if their total cholesterol concentration was above 3.5 mmol/L (135 mg/dL) and they were at a “substantial risk” for more than 5 years of death from coronary disease due to the presence of known cardiovascular disease (coronary artery disease, peripheral artery disease, cerebrovascular disease), diabetes, or hypertension. Patients were excluded if they had other life-threatening illnesses, diagnosed cancer, or were already taking high-dose vitamin E supplements.

STUDY DESIGN AND VALIDITY: Patients in this impressive placebo-controlled, double-blind randomized (masked allocation via central telephone system) trial received antioxidant supplementation (vitamin E 600 mg, vitamin C 250 mg, and beta-carotene 20 mg daily) or matching placebo. This study was part of the MRC/BHF study on simvastatin. All patients in the vitamin treatment group also received simvastatin. In an 8- to 10-week “prerandomization run-in” phase eligibility and compliance with the 5-year study protocol was assessed. Patients were seen at 4, 8, and 12 months, and then every 6 months during a 5-year period.

OUTCOMES MEASURED: The primary outcomes measured were “major coronary events” (nonfatal myocardial infarction or death from coronary disease) and fatal coronary heart disease. Secondary outcomes measured were effects on major coronary events and major vascular events and nonfatal or fatal stroke. Other outcomes included site-specific cancer, cerebral hemorrhage, vascular procedures, and hospitalization for various causes.

RESULTS: Patients taking vitamins had significantly higher levels of these vitamins in their blood. Despite this increase no difference was noted in all-cause mortality or deaths due to vascular or nonvascular causes. There were no differences in nonfatal myocardial infarctions, coronary death, nonfatal or fatal stroke, or coronary or noncoronary revascularization. No differences were noted in cancer incidence or hospitalization for any other nonvascular cause.

ABSTRACT

BACKGROUND: Several nonrandomized, observational studies have suggested that antioxidant vitamins decrease vascular disease, cancer, and mortality. However, large randomized trials are needed to counter biases such as the “healthy user effect” often seen in observational studies.

POPULATION STUDIED: The investigators studied 20,536 adults (mostly men from the United Kingdom) aged 40 to 80 years with diabetes, peripheral artery disease, or coronary artery disease. Patients were included if their total cholesterol concentration was above 3.5 mmol/L (135 mg/dL) and they were at a “substantial risk” for more than 5 years of death from coronary disease due to the presence of known cardiovascular disease (coronary artery disease, peripheral artery disease, cerebrovascular disease), diabetes, or hypertension. Patients were excluded if they had other life-threatening illnesses, diagnosed cancer, or were already taking high-dose vitamin E supplements.

STUDY DESIGN AND VALIDITY: Patients in this impressive placebo-controlled, double-blind randomized (masked allocation via central telephone system) trial received antioxidant supplementation (vitamin E 600 mg, vitamin C 250 mg, and beta-carotene 20 mg daily) or matching placebo. This study was part of the MRC/BHF study on simvastatin. All patients in the vitamin treatment group also received simvastatin. In an 8- to 10-week “prerandomization run-in” phase eligibility and compliance with the 5-year study protocol was assessed. Patients were seen at 4, 8, and 12 months, and then every 6 months during a 5-year period.

OUTCOMES MEASURED: The primary outcomes measured were “major coronary events” (nonfatal myocardial infarction or death from coronary disease) and fatal coronary heart disease. Secondary outcomes measured were effects on major coronary events and major vascular events and nonfatal or fatal stroke. Other outcomes included site-specific cancer, cerebral hemorrhage, vascular procedures, and hospitalization for various causes.

RESULTS: Patients taking vitamins had significantly higher levels of these vitamins in their blood. Despite this increase no difference was noted in all-cause mortality or deaths due to vascular or nonvascular causes. There were no differences in nonfatal myocardial infarctions, coronary death, nonfatal or fatal stroke, or coronary or noncoronary revascularization. No differences were noted in cancer incidence or hospitalization for any other nonvascular cause.

ABSTRACT

BACKGROUND: Several nonrandomized, observational studies have suggested that antioxidant vitamins decrease vascular disease, cancer, and mortality. However, large randomized trials are needed to counter biases such as the “healthy user effect” often seen in observational studies.

POPULATION STUDIED: The investigators studied 20,536 adults (mostly men from the United Kingdom) aged 40 to 80 years with diabetes, peripheral artery disease, or coronary artery disease. Patients were included if their total cholesterol concentration was above 3.5 mmol/L (135 mg/dL) and they were at a “substantial risk” for more than 5 years of death from coronary disease due to the presence of known cardiovascular disease (coronary artery disease, peripheral artery disease, cerebrovascular disease), diabetes, or hypertension. Patients were excluded if they had other life-threatening illnesses, diagnosed cancer, or were already taking high-dose vitamin E supplements.

STUDY DESIGN AND VALIDITY: Patients in this impressive placebo-controlled, double-blind randomized (masked allocation via central telephone system) trial received antioxidant supplementation (vitamin E 600 mg, vitamin C 250 mg, and beta-carotene 20 mg daily) or matching placebo. This study was part of the MRC/BHF study on simvastatin. All patients in the vitamin treatment group also received simvastatin. In an 8- to 10-week “prerandomization run-in” phase eligibility and compliance with the 5-year study protocol was assessed. Patients were seen at 4, 8, and 12 months, and then every 6 months during a 5-year period.

OUTCOMES MEASURED: The primary outcomes measured were “major coronary events” (nonfatal myocardial infarction or death from coronary disease) and fatal coronary heart disease. Secondary outcomes measured were effects on major coronary events and major vascular events and nonfatal or fatal stroke. Other outcomes included site-specific cancer, cerebral hemorrhage, vascular procedures, and hospitalization for various causes.

RESULTS: Patients taking vitamins had significantly higher levels of these vitamins in their blood. Despite this increase no difference was noted in all-cause mortality or deaths due to vascular or nonvascular causes. There were no differences in nonfatal myocardial infarctions, coronary death, nonfatal or fatal stroke, or coronary or noncoronary revascularization. No differences were noted in cancer incidence or hospitalization for any other nonvascular cause.